Literature DB >> 29321714

Cavum Vergae, Liability, and Steroid Treatment: Manic Episode, Brain Imaging Findings, and Clinical Follow-up of a Systemic Lupus Erythematosus Case.

Emre Misir1, İbrahim Tolga Binbay1, Bilge Targitay1, Hidayet Ece Arat2, Gerçek Can3, Köksal Alptekin1.   

Abstract

Systemic lupus erythematosus (SLE) or Lupus is a chronic and idiopathic autoimmune connective tissue disease that involves several organs and organ systems. SLE may lead to a group of psychiatric manifestations, including delirium, anxiety disorders, cognitive dysfunction, mood disorders, and psychosis, which are caused by organic or non-organic factors. In addition, it is thought that the most common cause of neuropsychiatric lupus is corticosteroid use; central nervous system involvement and inflammatory processes also have an important role in the development of psychiatric manifestations. In other respects, structural brain abnormalities induce proneness to psychotic and manic symptoms. Along with this proneness, cavum vergae, an anomaly closely related to the anatomic areas associated with mood regulation, may precipitate manic symptoms. In this case report, we present a manic episode case emerging after delirium, with a 1-year history of SLE, which has recently been diagnosed with cavum vergae and discuss the process of infection and corticosteroid treatment, which contributed to the proneness effect of a structural brain anomaly.

Entities:  

Keywords:  Systemic lupus eritematosus; cavum vergae; manic episode

Year:  2017        PMID: 29321714      PMCID: PMC5758084          DOI: 10.5152/npa.2017.18129

Source DB:  PubMed          Journal:  Noro Psikiyatr Ars        ISSN: 1300-0667            Impact factor:   1.339


  20 in total

1.  Psychiatric disorders in neurology patients.

Authors:  John Moriarty
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-11-10       Impact factor: 10.154

Review 2.  Systemic lupus erythematosus.

Authors:  Larissa Lisnevskaia; Grainne Murphy; David Isenberg
Journal:  Lancet       Date:  2014-05-31       Impact factor: 79.321

3.  Cava septi pellucidi et vergae: their normal and pathogical states.

Authors:  C M Shaw; E C Alvord
Journal:  Brain       Date:  1969-03       Impact factor: 13.501

4.  A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus.

Authors:  L A DeGiorgio; K N Konstantinov; S C Lee; J A Hardin; B T Volpe; B Diamond
Journal:  Nat Med       Date:  2001-11       Impact factor: 53.440

Review 5.  The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes.

Authors: 
Journal:  Arthritis Rheum       Date:  1999-04

6.  The clinical relevance of antibodies to ribosomal-P common epitope in two targeted systemic lupus erythematosus populations: a large cohort of consecutive patients and patients with active central nervous system disease.

Authors:  A G Tzioufas; N G Tzortzakis; E Panou-Pomonis; K A Boki; M Sakarellos-Daitsiotis; C Sakarellos; H M Moutsopoulos
Journal:  Ann Rheum Dis       Date:  2000-02       Impact factor: 19.103

7.  Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies.

Authors:  Giovanni Sanna; Maria L Bertolaccini; Maria J Cuadrado; Hana Laing; Munther A Khamashta; Alessandro Mathieu; Graham R V Hughes
Journal:  J Rheumatol       Date:  2003-05       Impact factor: 4.666

8.  Prevalence of large cavum septi pellucidi in ultra high-risk individuals and patients with psychotic disorders.

Authors:  Tsutomu Takahashi; Alison R Yung; Murat Yücel; Stephen J Wood; Lisa J Phillips; Ian H Harding; Bridget Soulsby; Patrick D McGorry; Michio Suzuki; Dennis Velakoulis; Christos Pantelis
Journal:  Schizophr Res       Date:  2008-08-06       Impact factor: 4.939

9.  Prevalence of mood and anxiety disorders in women with systemic lupus erythematosus.

Authors:  Elizabeth A Bachen; Margaret A Chesney; Lindsey A Criswell
Journal:  Arthritis Rheum       Date:  2009-06-15

10.  Neuropsychiatric systemic lupus erythematosus.

Authors:  Alexandra Popescu; Amy H Kao
Journal:  Curr Neuropharmacol       Date:  2011-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.